#United States #Shreveport #LSU Health #fetal monitoring #Raydiant Oximetry

Raydiant Oximetry Completes Patient Enrollment in Pilot Study

Raydiant Oximetry, a California-based medical device innovator, has made a significant stride in advancing fetal monitoring technology. The company recently announced the completion of its initial enrollment phase, successfully gathering data from the first fifteen patients participating in its Investigational Device Exemption (IDE) Pilot Study at Louisiana State University Health Shreveport (LSUHS). This study focuses on the use of their investigational transvaginal sensor aimed at enhancing fetal pulse oximetry measurements during labor.

Significance of the Study

The IDE Pilot Study is designed to collect comprehensive fetal pulse oximetry data, specifically recording information via a sensor placed on the cheek of the fetus during active labor. This technique intends to provide healthcare professionals with precise insights into the oxygen levels and overall well-being of the fetus, which can be critical during labor and delivery. Raydiant has already gathered more than 40 hours of valuable data from this cohort, enabling them to refine and advance their machine learning algorithms crucial for future commercial products.

Dr. P. Scott Barrilleaux, the study's Principal Investigator and an Associate Professor in Obstetrics and Gynecology at LSUHS, expressed his satisfaction with the clinical study. He highlighted the potential clinical value that fetal pulse oximetry can offer to healthcare providers, affirming their commitment to contribute to the future of this vital technology.

Expansion and Future Prospects

Following the positive initial results, the U.S. Food and Drug Administration (FDA) granted Raydiant Oximetry permission to expand their study, allowing them to enroll up to an additional fifteen patients. This expansion is a pivotal milestone, enabling Raydiant and LSUHS to deepen the dataset and further progress with product development to enhance fetal monitoring technologies.

Michael Nagel, CEO of Raydiant Oximetry, praised LSUHS as an exceptional clinical partner. He stated, "The collaboration has yielded substantial data during the initial phase of this IDE study. The FDA's approval to increase patient enrollment is a significant step forward, and we are eager to continue working with LSUHS to lay the foundation for an entirely new generation of fetal monitoring technologies that will enhance the safety and outcomes for mothers and babies alike."

Innovating Fetal Monitoring Technologies

Raydiant Oximetry is powered by a mission to transform fetal monitoring standards, an area that has not seen significant technological advancements over the past decades. Traditional fetal heart rate monitoring methods, while sensitive, often lack specificity in accurately predicting fetal hypoxia (low oxygen levels). Raydiant’s innovative solution aims to complement existing monitoring systems while delivering clearer insights regarding fetal oxygen status.

Founded by Dr. Neil P. Ray, a pediatric anesthesiologist, and supported by the Fogarty Innovation incubator, Raydiant is committed to enhancing the standard of care in labor and delivery. They strive to elevate the quality of monitoring to ultimately ensure better health outcomes for both mothers and their children.

For more information about Raydiant Oximetry and their pioneering efforts in fetal monitoring technology, visit raydiantoximetry.com.

About LSU Health Shreveport

LSU Health Shreveport stands as one of the primary health sciences centers in the LSU system and boasts the only academic medical center within a 150-mile radius. The institution's mission revolves around educating, healing, and discovering to enhance health and wellness in the community and beyond. With a robust focus on medical education, research, and community service, LSU Health Shreveport is dedicated to advancing healthcare initiatives in Louisiana.

Explore more at www.lsuhs.edu.